PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 273 filers reported holding PACIRA PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 3.03 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $234,000 | -5.6% | 4,404 | +3.6% | 0.00% | 0.0% |
| Q2 2022 | $248,000 | -23.5% | 4,250 | +0.1% | 0.00% | 0.0% |
| Q1 2022 | $324,000 | -27.8% | 4,245 | -43.1% | 0.00% | 0.0% |
| Q4 2021 | $449,000 | +12.2% | 7,454 | +4.4% | 0.00% | -33.3% |
| Q3 2021 | $400,000 | +22.0% | 7,142 | +32.1% | 0.00% | +50.0% |
| Q2 2021 | $328,000 | +3.1% | 5,407 | +19.1% | 0.00% | 0.0% |
| Q1 2021 | $318,000 | -16.3% | 4,540 | -28.5% | 0.00% | -50.0% |
| Q4 2020 | $380,000 | +21.0% | 6,352 | +21.7% | 0.00% | 0.0% |
| Q3 2020 | $314,000 | +30.8% | 5,219 | +14.0% | 0.00% | +33.3% |
| Q2 2020 | $240,000 | +8.1% | 4,577 | -6.7% | 0.00% | 0.0% |
| Q4 2019 | $222,000 | -32.9% | 4,908 | -43.6% | 0.00% | -40.0% |
| Q3 2019 | $331,000 | +32.4% | 8,702 | +51.3% | 0.01% | +25.0% |
| Q2 2019 | $250,000 | -47.1% | 5,751 | +7.9% | 0.00% | -96.3% |
| Q4 2014 | $473,000 | – | 5,331 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |